Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial

Background: Improved patient-reported outcomes (PROs) are increasingly becoming a key treatment objective in acromegaly. Validated PROs were used to assess disease and treatment burden in the MPOWERED phase 3 trial in acromegaly, which also assessed safety and efficacy of oral octreotide capsules (O...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Endocrine Society 2021-05, Vol.5 (Supplement_1), p.A520-A521
Hauptverfasser: Gordon, Murray B, Fleseriu, Maria, Dreval, Akexander V, Pokramovich, Yulia, Bondar, Irina, Isaeva, Elena, Molitch, Mark E, Macut, Djuro P, Leonova, Nina, Raverot, Gerald, Kirschner, Lawrence S, Chanson, Philippe, Gilgun-Sherki, Yossi, Ludlam, William H, Patou, Gary, Haviv, Asi, Biermasz, Nienke, Melmed, Shlomo, Strasburger, Christian J
Format: Artikel
Sprache:eng
Schlagworte:
Neuroendocrinology and Pituitary
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Improved patient-reported outcomes (PROs) are increasingly becoming a key treatment objective in acromegaly. Validated PROs were used to assess disease and treatment burden in the MPOWERED phase 3 trial in acromegaly, which also assessed safety and efficacy of oral octreotide capsules (OOC; MYCAPSSA®) compared to injectable SRLs (iSRLs). Methods: Eligible patients had acromegaly diagnosis, biochemical control of acromegaly (insulin-like growth factor I
ISSN:2472-1972
2472-1972
DOI:10.1210/jendso/bvab048.1062